Esoteric Testing Market By Type, By Technology, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

Description

List of Tables

The esoteric testing market was valued at $24.2 billion in 2022 and is estimated to reach $68.5 billion by 2032, exhibiting a CAGR of 11.0% from 2023 to 2032. Esoteric testing is defined as the analysis of rare molecules that are not performed in routine clinical labs. This analysis is done by using various technologies such as real time polymerase chain reaction, enzyme linked immunosorbent assay, flow cytometry, and DNA sequencing. These tests require specialized equipment and are performed on a small scale. It requires skilled personnel to conduct these tests and analyze the result by using various chemical agents and sophisticated instruments. Esoteric testing is generally performed for the diagnosis of rare diseases, infectious diseases, and endocrine diseases.

The esoteric testing market growth is significantly driven by increase in the prevalence of chronic diseases such as cancer, hypertension, diabetes and chronic infectious diseases; surge in awareness about importance of early disease diagnosis; and increase in new test launches. Esoteric tests are designed to detect specific markers to enable more precise diagnosis and prognosis of chronic diseases such as cancer and HIV. For instance, according to American Cancer Society (ACS), about 1.9 million new cancer cases are expected to be diagnosed in the U.S. in 2022. Thus, rise in prevalence of chronic diseases drives the demand for specialized, esoteric tests.

Furthermore, surge in awareness about early disease diagnosis among the general population has increased the demand for esoteric testing. Awareness campaigns, educational seminars, and training programs emphasize the importance of early disease diagnosis. For instance, F. Hoffmann-La Roche Ltd., supports local community partners to run screening programs and counselling programs for diseases such as cancers, hepatitis, tuberculosis, HIV, HPV, cardiovascular disease and diabetes. Moreover, technological advancements and new product launches further drive the market growth. For instance, Laboratory Corporation of America Holdings, a global life sciences company, launched its new Neurofilament Light Chain (NfL) blood test that provides direct evidence of neurodegeneration and neuronal injury. This test will allow doctors to identify and verify signs of neurodegenerative diseases.

However, the high cost associated with esoteric testing and lack of skilled laboratory technicians are anticipated to hinder the market growth during the forecast period. On the other hand, increase in the number of diagnostic testing and technological advancements in DNA sequencing are expected to create lucrative opportunities for market growth during the forecast period.

The esoteric testing market is segmented into type, technology, end user, and region. By type, the market is categorized into infectious disease testing, oncology testing, endocrinology testing, genetic testing, toxicology testing, immunology testing, neurology testing, and other testing. By technology, the market is divided into enzyme-linked immunosorbent assay, chemiluminescence immunoassay, mass-spectrometry, real time polymerase chain reaction, DNA sequencing, flow cytometry, and other technologies. By end user, the market is bifurcated into hospital-based laboratories and independent & reference laboratories. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global esoteric testing market are Laboratory Corporation of America Holdings, ARUP Laboratories, Opko Health, Inc., Quest Diagnostics Inc., F. Hoffmann-La Roche Ltd., Mayo Foundation for Medical Education and Research, Stanford Health Care, Healius Limited, Athena Esoterix, LLC, and Sonic Healthcare Limited. Key players operating in the market have adopted product launch, collaboration, and product approval as key strategies to expand their market share and product portfolio.

Key Benefits for Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the esoteric testing market analysis from 2022 to 2032 to identify the prevailing esoteric testing market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the esoteric testing market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global esoteric testing market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Regulatory Guidelines
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
SWOT Analysis

Key Market Segments

By Type

Infectious Disease Testing
Oncology Testing
Endocrinology Testing
Genetic Testing
Toxicology Testing
Immunology Testing
Neurology Testing
Other Testings

By Technology

Enzyme-linked Immunosorbent Assay
Chemiluminescence Immunoassay
Mass Spectrometry
Real Time Polymerase Chain Reaction
DNA Sequencing
Flow Cytometry
Other Technologies

By End User

Hospital-based Laboratories
Independent and Reference Laboratories

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

ARUP Laboratories
Quest Diagnostics Inc.
F. Hoffmann-La Roche Ltd.
Stanford Health Care
Healius Limited
Laboratory Corporation of America Holdings
Opko Health, Inc.
Mayo Foundation for Medical Education and Research
Athena Esoterix, LLC.
Sonic Healthcare Limited

Product Code: A12022

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. High bargaining power of suppliers
- 3.3.2. Moderate threat of new entrants
- 3.3.3. Moderate threat of substitutes
- 3.3.4. Moderate intensity of rivalry
- 3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Increase in prevalence of chronic and infectious diseases
  - 3.4.1.2. Increase in awareness about early disease diagnosis and personalized medicine
  - 3.4.1.3. Increase in number of medical laboratories
- 3.4.2. Restraints
  - 3.4.2.1. High cost of esoteric testing
- 3.4.3. Opportunities
  - 3.4.3.1. Technological advancements in esoteric testing

CHAPTER 4: ESOTERIC TESTING MARKET, BY TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Infectious Disease Testing
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Oncology Testing
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Endocrinology Testing
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
4.5. Genetic Testing
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country
4.6. Toxicology Testing
- 4.6.1. Key market trends, growth factors and opportunities
- 4.6.2. Market size and forecast, by region
- 4.6.3. Market share analysis by country
4.7. Immunology Testing
- 4.7.1. Key market trends, growth factors and opportunities
- 4.7.2. Market size and forecast, by region
- 4.7.3. Market share analysis by country
4.8. Neurology Testing
- 4.8.1. Key market trends, growth factors and opportunities
- 4.8.2. Market size and forecast, by region
- 4.8.3. Market share analysis by country
4.9. Other Testings
- 4.9.1. Key market trends, growth factors and opportunities
- 4.9.2. Market size and forecast, by region
- 4.9.3. Market share analysis by country

CHAPTER 5: ESOTERIC TESTING MARKET, BY TECHNOLOGY

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Enzyme-linked Immunosorbent Assay
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Chemiluminescence Immunoassay
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Mass Spectrometry
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
5.5. Real Time Polymerase Chain Reaction
- 5.5.1. Key market trends, growth factors and opportunities
- 5.5.2. Market size and forecast, by region
- 5.5.3. Market share analysis by country
5.6. DNA Sequencing
- 5.6.1. Key market trends, growth factors and opportunities
- 5.6.2. Market size and forecast, by region
- 5.6.3. Market share analysis by country
5.7. Flow Cytometry
- 5.7.1. Key market trends, growth factors and opportunities
- 5.7.2. Market size and forecast, by region
- 5.7.3. Market share analysis by country
5.8. Other Technologies
- 5.8.1. Key market trends, growth factors and opportunities
- 5.8.2. Market size and forecast, by region
- 5.8.3. Market share analysis by country

CHAPTER 6: ESOTERIC TESTING MARKET, BY END USER

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospital-based Laboratories
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Independent and Reference Laboratories
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country

CHAPTER 7: ESOTERIC TESTING MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by Type
- 7.2.3. Market size and forecast, by Technology
- 7.2.4. Market size and forecast, by End User
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Market size and forecast, by Type
  - 7.2.5.1.2. Market size and forecast, by Technology
  - 7.2.5.1.3. Market size and forecast, by End User
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Market size and forecast, by Type
  - 7.2.5.2.2. Market size and forecast, by Technology
  - 7.2.5.2.3. Market size and forecast, by End User
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Market size and forecast, by Type
  - 7.2.5.3.2. Market size and forecast, by Technology
  - 7.2.5.3.3. Market size and forecast, by End User
7.3. Europe
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by Type
- 7.3.3. Market size and forecast, by Technology
- 7.3.4. Market size and forecast, by End User
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Market size and forecast, by Type
  - 7.3.5.1.2. Market size and forecast, by Technology
  - 7.3.5.1.3. Market size and forecast, by End User
  - 7.3.5.2. France
  - 7.3.5.2.1. Market size and forecast, by Type
  - 7.3.5.2.2. Market size and forecast, by Technology
  - 7.3.5.2.3. Market size and forecast, by End User
  - 7.3.5.3. UK
  - 7.3.5.3.1. Market size and forecast, by Type
  - 7.3.5.3.2. Market size and forecast, by Technology
  - 7.3.5.3.3. Market size and forecast, by End User
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Market size and forecast, by Type
  - 7.3.5.4.2. Market size and forecast, by Technology
  - 7.3.5.4.3. Market size and forecast, by End User
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Market size and forecast, by Type
  - 7.3.5.5.2. Market size and forecast, by Technology
  - 7.3.5.5.3. Market size and forecast, by End User
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Market size and forecast, by Type
  - 7.3.5.6.2. Market size and forecast, by Technology
  - 7.3.5.6.3. Market size and forecast, by End User
7.4. Asia-Pacific
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by Type
- 7.4.3. Market size and forecast, by Technology
- 7.4.4. Market size and forecast, by End User
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Market size and forecast, by Type
  - 7.4.5.1.2. Market size and forecast, by Technology
  - 7.4.5.1.3. Market size and forecast, by End User
  - 7.4.5.2. China
  - 7.4.5.2.1. Market size and forecast, by Type
  - 7.4.5.2.2. Market size and forecast, by Technology
  - 7.4.5.2.3. Market size and forecast, by End User
  - 7.4.5.3. India
  - 7.4.5.3.1. Market size and forecast, by Type
  - 7.4.5.3.2. Market size and forecast, by Technology
  - 7.4.5.3.3. Market size and forecast, by End User
  - 7.4.5.4. Australia
  - 7.4.5.4.1. Market size and forecast, by Type
  - 7.4.5.4.2. Market size and forecast, by Technology
  - 7.4.5.4.3. Market size and forecast, by End User
  - 7.4.5.5. Rest of Asia-Pacific
  - 7.4.5.5.1. Market size and forecast, by Type
  - 7.4.5.5.2. Market size and forecast, by Technology
  - 7.4.5.5.3. Market size and forecast, by End User
7.5. LAMEA
- 7.5.1. Key market trends, growth factors and opportunities
- 7.5.2. Market size and forecast, by Type
- 7.5.3. Market size and forecast, by Technology
- 7.5.4. Market size and forecast, by End User
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Market size and forecast, by Type
  - 7.5.5.1.2. Market size and forecast, by Technology
  - 7.5.5.1.3. Market size and forecast, by End User
  - 7.5.5.2. Saudi Arabia
  - 7.5.5.2.1. Market size and forecast, by Type
  - 7.5.5.2.2. Market size and forecast, by Technology
  - 7.5.5.2.3. Market size and forecast, by End User
  - 7.5.5.3. South Africa
  - 7.5.5.3.1. Market size and forecast, by Type
  - 7.5.5.3.2. Market size and forecast, by Technology
  - 7.5.5.3.3. Market size and forecast, by End User
  - 7.5.5.4. Rest of LAMEA
  - 7.5.5.4.1. Market size and forecast, by Type
  - 7.5.5.4.2. Market size and forecast, by Technology
  - 7.5.5.4.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

9.1. Laboratory Corporation of America Holdings
- 9.1.1. Company overview
- 9.1.2. Key executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
9.2. ARUP Laboratories
- 9.2.1. Company overview
- 9.2.2. Key executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
9.3. Mayo Foundation for Medical Education and Research
- 9.3.1. Company overview
- 9.3.2. Key executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
9.4. Healius Limited
- 9.4.1. Company overview
- 9.4.2. Key executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
9.5. Opko Health, Inc.
- 9.5.1. Company overview
- 9.5.2. Key executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.5.7. Key strategic moves and developments
9.6. Quest Diagnostics Inc.
- 9.6.1. Company overview
- 9.6.2. Key executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.6.7. Key strategic moves and developments
9.7. Sonic Healthcare Limited
- 9.7.1. Company overview
- 9.7.2. Key executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
9.8. F. Hoffmann-La Roche Ltd.
- 9.8.1. Company overview
- 9.8.2. Key executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
9.9. Stanford Health Care
- 9.9.1. Company overview
- 9.9.2. Key executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
9.10. Athena Esoterix, LLC.
- 9.10.1. Company overview
- 9.10.2. Key executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio